Medical Oncology

, Volume 27, Issue 3, pp 646–653 | Cite as

Multiple myeloma: management of adverse events

Original Paper


The combination of conventional chemotherapy or dexamethasone with new drugs, such as immunomodulatory agents and proteasome inhibitors, has substantially changed the treatment paradigm of myeloma patients. New drugs have been incorporated in pre-transplant induction regimens and post-transplant consolidation and maintenance strategies for young patients; in elderly patients, standard melphalan and prednisone (MP) plus thalidomide or plus bortezomib are now considered standards of care, and ongoing trials are assessing if lenalidomide plus standard MP or plus low-dose dexamethasone may be other options. The efficacy of these drugs needs to be balanced against their toxicity. Different drugs have a different toxicity profile. The choice for the best treatment strategy for every single patient should be based on results of scientific randomized studies but tailored to account for patient’s biological age, comorbidities, and the expected toxicity profile of different regimens. Prompt dose reduction and accurate management of treatment-related toxicity can greatly reduce early discontinuation rate and significantly improve treatment efficacy. This chapter will focus on frequency and management of main adverse events in newly diagnosed and relapsed myeloma patients and will provide guidelines for dose reductions and supportive therapy.


Myeloma Adverse events Therapy New drugs 


  1. 1.
    Macro M, et al. Dexamethasone + thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial. Blood. 2006;108(11):57.Google Scholar
  2. 2.
    Rajkumar SV, Blood E, Vesole DH, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Rajkumar SV, et al. A multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone versus dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26:2171–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Rajkumar SV, et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome with transplantation. J Clin Oncol. 2008;26(15 suppl):8504.Google Scholar
  5. 5.
    Zonder JA, et al. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232. Blood. 2007;110(11):77.Google Scholar
  6. 6.
    Harousseau JL, et al. VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial. Blood. 2007;110(11):450.Google Scholar
  7. 7.
    Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol. 2008;26(3):480–92.CrossRefPubMedGoogle Scholar
  8. 8.
    Palumbo A, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825–31.CrossRefPubMedGoogle Scholar
  9. 9.
    Facon T, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet. 2007;370(9594):1209–18.CrossRefPubMedGoogle Scholar
  10. 10.
    San Miguel JF, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17.CrossRefPubMedGoogle Scholar
  11. 11.
    Richardson PG, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–98.CrossRefPubMedGoogle Scholar
  12. 12.
    Orlowski RZ, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892–901.CrossRefPubMedGoogle Scholar
  13. 13.
    Weber DM, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133–42.CrossRefPubMedGoogle Scholar
  14. 14.
    Dimopoulos M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Fermand J-P, et al. A randomized comparison of dexamethasone + thalidomide (Dex/Thal) vs dex + placebo (Dex/P) in patients (pts) with relapsing multiple myeloma (MM). Blood. 2006;108(11):3563.Google Scholar
  16. 16.
    Reece Donna E, et al. Lenalidomide (Revlimid®) ± corticosteroids in elderly patients with relapsed/refractory multiple myeloma. Blood. 2006;108(11):3550.Google Scholar
  17. 17.
    Chanan-Khan AA, et al. Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): analysis from MM-009 and MM-010 randomized phase III clinical trials. Blood. 2006;108(11):3554.Google Scholar
  18. 18.
    Weber D, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. Blood. 2006;108(11):3547.Google Scholar
  19. 19.
    Lacy MQ, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007;82(10):1179–84.CrossRefPubMedGoogle Scholar
  20. 20.
    Palumbo A, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA Italian multiple myeloma network. J Clin Oncol. 2007;25(28):4459–65.CrossRefPubMedGoogle Scholar
  21. 21.
    Mateos M, et al. Bortezomib (Velcade)-melphalan-prednisone (VMP) versus velcade- thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: which is the best partner for velcade: an alkylating or an immunomodulator agent? Blood. 2008;112:651.Google Scholar
  22. 22.
    Palumbo A, et al. A prospective, randomized, phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients. Blood. 2008;112:652.CrossRefGoogle Scholar
  23. 23.
    Palumbo A, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111(8):3968–77.CrossRefPubMedGoogle Scholar
  24. 24.
    Richardson P, et al. The treatment of relapsed and refractory multiple myeloma hematology. Am Soc Hematol Educ Program 2007;317–323.Google Scholar
  25. 25.
    Richardson PG, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):895–903.CrossRefPubMedGoogle Scholar
  26. 26.
    Palumbo A, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414–23.CrossRefPubMedGoogle Scholar
  27. 27.
    Hulin C, et al. Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients ≥ 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood. 2007;110(11):75.Google Scholar
  28. 28.
    Wijermans P, et al. Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch Cooperative Group HOVON 49 study. Blood. 2008;112(11):649.Google Scholar
  29. 29.
    Cavo M, et al. A phase III study of enoxaparin versus low-dose warfarin versus aspirin as thromboprophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide-containing regimens. Blood. 2008;112(11):3017.Google Scholar
  30. 30.
    Palumbo A, et al. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Rev. 2009;23(2):87–93.CrossRefPubMedGoogle Scholar
  31. 31.
    Smith A, Samson D. UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132(4):410–51.Google Scholar
  32. 32.
    WHO. WHO guidelines: cancer pain relief. 2nd ed. Geneva: World Health Organization; 1986.Google Scholar
  33. 33.
    Terpos E, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009 (Epub ahead of print).Google Scholar
  34. 34.
    Leigh BR, Mack CF, Matzner MB, Shimm DS. Radiation therapy for the palliation of multiple myeloma. Int J Radiat Oncol Biol Phys. 1993;25(5):801–4.PubMedGoogle Scholar
  35. 35.
    Hussein MA, et al. International Myeloma Working Group. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia 2008;22(8):1479–84.Google Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  1. 1.Divisione di Ematologia dell’Università di TorinoAzienda Ospedaliera S. Giovanni BattistaTorinoItaly

Personalised recommendations